| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Debashis Dutta, Ramesh Kumar Paidi, Sumita Raha, Avik Roy, Sujyoti Chandra, Kalipada Paha. Treadmill exercise reduces α-synuclein spreading via PPARα. Cell reports. vol 40. issue 2. 2022-07-13. PMID:35830804. |
preformed α-syn fibril (pff) seeding in the internal capsule of young a53t α-syn mice leads to increased spreading of α-syn to substantia nigra and motor cortex and concomitant loss of nigral dopaminergic neurons. |
2022-07-13 |
2023-08-14 |
mouse |
| Xin-Xing Yang, Rong Yang, Feng Zhan. Role of Nrf2 in Parkinson's Disease: Toward New Perspectives. Frontiers in pharmacology. vol 13. 2022-07-11. PMID:35814229. |
the main pathology of pd formation is the progressive loss of dopaminergic neurons in substantia nigra and the formation of α-synuclein-rich lewy bodies. |
2022-07-11 |
2023-08-14 |
Not clear |
| Marta Lancione, Graziella Donatelli, Eleonora Del Prete, Nicole Campese, Daniela Frosini, Matteo Cencini, Mauro Costagli, Laura Biagi, Giacomo Lucchi, Michela Tosetti, Massimiliano Godani, Dario Arnaldi, Michele Terzaghi, Federica Provini, Claudio Pacchetti, Pietro Cortelli, Enrica Bonanni, Roberto Ceravolo, Mirco Cosottin. Evaluation of iron overload in Nigrosome 1 via Quantitative Susceptibility Mapping as a progression biomarker in prodromal stages of synucleinopathies. NeuroImage. 2022-07-10. PMID:35810938. |
idiopathic rapid eye movement (rem) sleep behavior disorder (irbd) is a prodromal stage of α-synucleinopathies, such as parkinson's disease (pd), which are characterized by the loss of dopaminergic neurons in substantia nigra, associated with abnormal iron load. |
2022-07-10 |
2023-08-14 |
human |
| Thomas Goiran, Mohamed A Eldeeb, Cornelia E Zorca, Edward A Fo. Hallmarks and Molecular Tools for the Study of Mitophagy in Parkinson's Disease. Cells. vol 11. issue 13. 2022-07-09. PMID:35805181. |
the best-known hallmarks of parkinson's disease (pd) are the motor deficits that result from the degeneration of dopaminergic neurons in the substantia nigra. |
2022-07-09 |
2023-08-14 |
Not clear |
| Devdutta S Warhadpande, Jiayan Huo, William A Libling, Carol Stuehm, Bijan Najafi, Scott Sherman, Hong Lei, Janet Meiling Roveda, Phillip H Ku. Pilot Study for Correlation of Heart Rate Variability and Dopamine Transporter Brain Imaging in Patients with Parkinsonian Syndrome. Sensors (Basel, Switzerland). vol 22. issue 13. 2022-07-09. PMID:35808551. |
parkinson disease (pd) is the second most common neurodegenerative disorder with loss of dopaminergic neurons of the substantia nigra and, thus, dysfunction of the nigrostriatal pathway. |
2022-07-09 |
2023-08-14 |
Not clear |
| Chun-Bo Hu, Hui Jiang, Yin Yang, Guo-Hua Wang, Qiu-Hong Ji, Zhong-Zheng Jia, Li-Hua Shen, Qian-Qian Lu. DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson's disease. Neural regeneration research. vol 18. issue 1. 2022-07-08. PMID:35799542. |
we found that nbp greatly alleviated rotenone-induced motor disturbance in the rat model of parkinson's disease, inhibited loss of dopaminergic neurons and aggregation of α-synuclein, and reduced iron deposition in the substantia nigra and iron content in serum. |
2022-07-08 |
2023-08-14 |
rat |
| Samir Kumar Beura, Abhishek Ramachandra Panigrahi, Pooja Yadav, Sunil Kumar Sing. Role of Platelet in Parkinson's Disease: Insights into Pathophysiology & Theranostic Solutions. Ageing research reviews. 2022-07-07. PMID:35798236. |
gradual death and progressive loss of dopaminergic neurons in the pars compacta region of substantia nigra results in striatal dopamine deficiency in pd. |
2022-07-07 |
2023-08-14 |
Not clear |
| Anita Siller, Nadja T Hofer, Giulia Tomagra, Nicole Wiederspohn, Simon Hess, Julia Benkert, Aisylu Gaifullina, Desiree Spaich, Johanna Duda, Christina Poetschke, Kristina Vilusic, Eva Maria Fritz, Toni Schneider, Peter Kloppenburg, Birgit Liss, Valentina Carabelli, Emilio Carbone, Nadine Jasmin Ortner, Jörg Striessni. rβ2-subunit alternative splicing stabilizes Cav2.3 Ca eLife. vol 11. 2022-07-06. PMID:35792082. |
rβ2-subunit alternative splicing stabilizes cav2.3 ca in dopaminergic (da) substantia nigra (sn) neurons cav2.3 r-type ca |
2022-07-06 |
2023-08-14 |
Not clear |
| Lei Wang, Xinghong Wu, Ge Yang, Nan Hu, Zijian Zhao, Lei Zhao, Shengyu L. Cannabidiol alleviates the damage to dopaminergic neurons in MPTP-induced Parkinson's disease mice via regulating neuronal apoptosis and neuroinflammation. Neuroscience. 2022-07-06. PMID:35792194. |
the main pathological feature of pd is the loss or apoptosis of dopaminergic neurons in the substantia nigra (sn). |
2022-07-06 |
2023-08-14 |
mouse |
| Sherin Abubakr Abdelrahman, Walaa F Alsanie, Zainab N Khan, Hamed I Albalawi, Raed I Felimban, Manola Moretti, Nadia Steiner, Adeel G Chaudhary, Charlotte A E Hause. A Parkinson's disease model composed of 3D bioprinted dopaminergic neurons within a biomimetic peptide scaffold. Biofabrication. 2022-07-06. PMID:35793642. |
it is associated with lost dopaminergic neurons in the substantia nigra, a process that is not yet fully understood. |
2022-07-06 |
2023-08-14 |
mouse |
| Amnon A Berger, Ariel Winnick, Jonathan Izygon, Binil M Jacob, Jessica S Kaye, Rachel J Kaye, Elisa E Neuchat, Adam M Kaye, Edward S Alpaugh, Elyse M Cornett, Andrew H Han, Alan D Kay. Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson's Disease "Off" Episodes. Health psychology research. vol 10. issue 3. 2022-07-01. PMID:35774903. |
the traditional pathogenesis theory of pd involves the loss of dopaminergic neurons in the substantia nigra (sn). |
2022-07-01 |
2023-08-14 |
Not clear |
| Thomas Musacchio, Jing Yin, Fabian Kremer, James B Koprich, Jonathan M Brotchie, Jens Volkmann, Chi Wang I. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease. Behavioural brain research. 2022-06-23. PMID:35738338. |
a differential intraneuronal vulnerability of dopaminergic neurons within the substantia nigra (sn) has been suggested, starting as an axonopathy followed by neuronal cell loss that is accompanied with motor deficits. |
2022-06-23 |
2023-08-14 |
human |
| Binlin Xu, Xiaoquan Wang, Zhengshuang Xu, Qinkai Li, Junmin Qua. N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease. Neuroscience letters. 2022-06-23. PMID:35738458. |
parkinson's disease (pd) is a common neurodegenerative disease characterized by the progressive loss of dopaminergic (da) neurons in the substantia nigra (sn), which is highly associated with oxidative stress. |
2022-06-23 |
2023-08-14 |
mouse |
| Isaac Deng, Sanjay Garg, Xin-Fu Zhou, Larisa Bobrovskay. The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease. Frontiers in bioscience (Scholar edition). vol 14. issue 2. 2022-06-22. PMID:35730438. |
the major hallmark of parkinson's disease (pd) is the degeneration of dopaminergic neurons in the substantia nigra (sn), which is responsible for the core motor symptoms of pd. |
2022-06-22 |
2023-08-14 |
mouse |
| Julian Krauskopf, Kristel Eggermont, Rodrigo Furtado Madeiro Da Costa, Sacha Bohler, Duncan Hauser, Florian Caiment, Theo M de Kok, Catherine Verfaillie, Jos C Kleinjan. Transcriptomics analysis of human iPSC-derived dopaminergic neurons reveals a novel model for sporadic Parkinson's disease. Molecular psychiatry. 2022-06-21. PMID:35725899. |
as pd is characterized by a loss of dopaminergic neurons in the substantia nigra, it is nearly impossible to access and extract these cells from patients for investigating disease mechanisms. |
2022-06-21 |
2023-08-14 |
human |
| Arjun Patel, Catherine A Olang, Gregory Lewis, Kesava Mandalaneni, Nikhilesh Anand, Vasavi Rakesh Gorantl. An Overview of Parkinson's Disease: Curcumin as a Possible Alternative Treatment. Cureus. vol 14. issue 5. 2022-06-20. PMID:35719816. |
parkinson's disease (pd) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra of the midbrain and basal ganglia, followed by dopamine deficiency in the brain. |
2022-06-20 |
2023-08-14 |
Not clear |
| Zhenhua Liu, Nannan Yang, Jie Dong, Wotu Tian, Lisa Chang, Jinghong Ma, Jifeng Guo, Jieqiong Tan, Ao Dong, Kaikai He, Jingheng Zhou, Resat Cinar, Junbing Wu, Armando G Salinas, Lixin Sun, Mantosh Kumar, Breanna T Sullivan, Braden B Oldham, Vanessa Pitz, Mary B Makarious, Jinhui Ding, Justin Kung, Chengsong Xie, Sarah L Hawes, Lupeng Wang, Tao Wang, Piu Chan, Zhuohua Zhang, Weidong Le, Shengdi Chen, David M Lovinger, Cornelis Blauwendraat, Andrew B Singleton, Guohong Cui, Yulong Li, Huaibin Cai, Beisha Tan. Deficiency in endocannabinoid synthase DAGLB contributes to early onset Parkinsonism and murine nigral dopaminergic neuron dysfunction. Nature communications. vol 13. issue 1. 2022-06-17. PMID:35715418. |
daglb is the main 2-ag synthase in human and mouse substantia nigra (sn) dopaminergic neurons (dans). |
2022-06-17 |
2023-08-14 |
mouse |
| Carmen M Labandeira, Maria A Pedrosa, Aloia Quijano, Rita Valenzuela, Pablo Garrido-Gil, Mariña Sanchez-Andrade, Juan A Suarez-Quintanilla, Ana I Rodriguez-Perez, Jose L Labandeira-Garci. Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease. NPJ Parkinson's disease. vol 8. issue 1. 2022-06-14. PMID:35701430. |
consistent with the observations in patients, experimental dopaminergic degeneration, induced by 6-hydroxydopamine, increased levels of autoantibodies in serum and csf in rats, as well as light levels and transglutaminase activity in rat substantia nigra. |
2022-06-14 |
2023-08-14 |
rat |
| Marta Esteves, Ricardo Abreu, Hugo Fernandes, Catarina Serra-Almeida, Patrícia A T Martins, Marta Barão, Ana Clara Cristóvão, Cláudia Saraiva, Raquel Ferreira, Lino Ferreira, Liliana Bernardin. MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's disease. Molecular therapy : the journal of the American Society of Gene Therapy. 2022-06-11. PMID:35689381. |
parkinson's disease is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra with no effective cure available. |
2022-06-11 |
2023-08-14 |
mouse |
| Marta Esteves, Ricardo Abreu, Hugo Fernandes, Catarina Serra-Almeida, Patrícia A T Martins, Marta Barão, Ana Clara Cristóvão, Cláudia Saraiva, Raquel Ferreira, Lino Ferreira, Liliana Bernardin. MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's disease. Molecular therapy : the journal of the American Society of Gene Therapy. 2022-06-11. PMID:35689381. |
most importantly, although mir-124-3p-loaded small extracellular vesicles did not increase the number of new neurons in the 6-hydroxydopamine-lesioned striatum, the formulation protected dopaminergic neurons in the substantia nigra and striatal fibers, which fully counteracted motor behavior symptoms. |
2022-06-11 |
2023-08-14 |
mouse |